CRISPR Therapeutics, Inc.

ToolGen has filed a patent infringement lawsuit in the Netherlands against Lonza, alleging unauthorized use of its CRISPR-Cas9 RNP technology in producing CASGEVY, the world's first approved gene-editing therapy.

Vertex Pharmaceuticals has committed $45 million upfront to partner with Enlaza Therapeutics, with potential total deal value exceeding $2 billion for autoimmune disease treatments.

The follicular lymphoma market is projected to grow at a 6% CAGR during 2025-2034, driven by increased disease awareness and rising number of clinical trials focused on this slow-growing B-cell malignancy.

The anti-GPC3 targeted therapies market is expected to surge significantly by 2040, driven by increasing cancer incidence and clinical pipeline activity across hepatocellular carcinoma, non-small cell lung cancer, and gastric cancer.

CRISPR Therapeutics' CTX310, an in vivo ANGPTL3 knockout therapy, demonstrated peak reductions of up to 82% in triglycerides and 86% in LDL cholesterol at dose level four in Phase 1 trial results.

Oruka Therapeutics has promoted Laura Sandler to Chief Operating Officer, leveraging her 20+ years of biopharmaceutical experience including her role in advancing CRISPR's first approved therapy exa-cel.

CRISPR Therapeutics reported initial top-line results from an early-stage study on CTX310, showing peak reductions of up to 82% in triglycerides and 81% in LDL cholesterol with a single dose.

Tourmaline Bio's antibody drug pacibekitug demonstrated significant reduction in cardiovascular risk biomarkers compared to placebo in Phase 2 trials, but shares fell 18% as investors question its competitive edge against Novo Nordisk's offering.

CRISPR Therapeutics is diversifying beyond gene editing through a strategic $95 million partnership with Sirius Therapeutics to develop SRSD107, a long-acting siRNA therapy targeting Factor XI for thromboembolic disorders.

Capsida Biotherapeutics has received FDA IND clearance for CAP-002, the first intravenously administered gene therapy that crosses the blood-brain barrier while avoiding off-target tissues for STXBP1-DEE.